JNJ241220C150000
- 0.07
- -0.17-70.83%
Johnson & Johnson Newsroom
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab
Dow's 111-Point Drop Led By Losses For UnitedHealth, Verizon Shares
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Another Week, Another Index Record | Lkive Stock
Express News | J&J: Submits Application Seeking U.S. FDA Approval of Simponi® (Golimumab) for Treatment of Pediatric Ulcerative Colitis
Insider Trades: Kroger, Johnson & Johnson Among Notable Names This Week
Weekly Buzz: Tech stocks hit high scores on ominous day
J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- WSJ
Express News | Johnson & Johnson Shares up 0.4%
Express News | Cigna Shares Pare Gains, Last up 0.2%; Wall Street Journal Reports Johnson & Johnson Has Sued Divisions of Cigna
"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical Company Claims Cigna Units Worked With SaveOn and Caused It to Pay More Than $100 Million in Copay Assistance Than It Would Have Otherwise" - WSJ
Johnson & Johnson Options Trading: A Deep Dive Into Market Sentiment
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ACTION Centers Collaborate With Johnson & Johnson MedTech to Secure FDA Labeling for Impella Support System in Pediatric Patients
Market Mixed on Friday the 13th | Livestock
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Insider Purchase: Director at $JNJ (JNJ) Buys 1,000 Shares